SMOC2

Across TCGA pan-cancer cohorts, SMOC2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SMOC2 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMOC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMOC2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, UCEC, and HNSC are the cancer types where SMOC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.526	0.800	.023	26	view →
UCEC	OS	Tertile	II,III,IV	0.494	1.000	.016	16	view →
HNSC	DFS	Quartile	III,IV	0.978	0.527	.018	10	view →
LUAD	DFS	Median	All	0.718	0.440	.008	8	view →
COAD	DFS	Median	III,IV	0.750	1.000	.033	6	view →
GBM	DFS	Median	All	0.600	0.859	.003	3	view →
LSCC	OS	Median	II,III,IV	0.903	1.000	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SMOC2–CCRCC (DFS)

Open the CCRCC breakdown →